Cargando…
Validation strategies for antibodies targeting modified ribonucleotides
Chemical modifications are found on almost all RNAs and affect their coding and noncoding functions. The identification of m(6)A on mRNA and its important role in gene regulation stimulated the field to investigate whether additional modifications are present on mRNAs. Indeed, modifications includin...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491328/ https://www.ncbi.nlm.nih.gov/pubmed/32636310 http://dx.doi.org/10.1261/rna.076026.120 |
_version_ | 1783582200882528256 |
---|---|
author | Weichmann, Franziska Hett, Robert Schepers, Aloys Ito-Kureha, Taku Flatley, Andrew Slama, Kaouthar Hastert, Florian D. Angstman, Nicholas B. Cardoso, M. Cristina König, Julian Hüttelmaier, Stefan Dieterich, Christoph Canzar, Stefan Helm, Mark Heissmeyer, Vigo Feederle, Regina Meister, Gunter |
author_facet | Weichmann, Franziska Hett, Robert Schepers, Aloys Ito-Kureha, Taku Flatley, Andrew Slama, Kaouthar Hastert, Florian D. Angstman, Nicholas B. Cardoso, M. Cristina König, Julian Hüttelmaier, Stefan Dieterich, Christoph Canzar, Stefan Helm, Mark Heissmeyer, Vigo Feederle, Regina Meister, Gunter |
author_sort | Weichmann, Franziska |
collection | PubMed |
description | Chemical modifications are found on almost all RNAs and affect their coding and noncoding functions. The identification of m(6)A on mRNA and its important role in gene regulation stimulated the field to investigate whether additional modifications are present on mRNAs. Indeed, modifications including m(1)A, m(5)C, m(7)G, 2′-OMe, and Ψ were detected. However, since their abundances are low and tools used for their corroboration are often not well characterized, their physiological relevance remains largely elusive. Antibodies targeting modified nucleotides are often used but have limitations such as low affinity or specificity. Moreover, they are not always well characterized and due to the low abundance of the modification, particularly on mRNAs, generated data sets might resemble noise rather than specific modification patterns. Therefore, it is critical that the affinity and specificity is rigorously tested using complementary approaches. Here, we provide an experimental toolbox that allows for testing antibody performance prior to their use. |
format | Online Article Text |
id | pubmed-7491328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cold Spring Harbor Laboratory Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-74913282021-10-01 Validation strategies for antibodies targeting modified ribonucleotides Weichmann, Franziska Hett, Robert Schepers, Aloys Ito-Kureha, Taku Flatley, Andrew Slama, Kaouthar Hastert, Florian D. Angstman, Nicholas B. Cardoso, M. Cristina König, Julian Hüttelmaier, Stefan Dieterich, Christoph Canzar, Stefan Helm, Mark Heissmeyer, Vigo Feederle, Regina Meister, Gunter RNA Method Chemical modifications are found on almost all RNAs and affect their coding and noncoding functions. The identification of m(6)A on mRNA and its important role in gene regulation stimulated the field to investigate whether additional modifications are present on mRNAs. Indeed, modifications including m(1)A, m(5)C, m(7)G, 2′-OMe, and Ψ were detected. However, since their abundances are low and tools used for their corroboration are often not well characterized, their physiological relevance remains largely elusive. Antibodies targeting modified nucleotides are often used but have limitations such as low affinity or specificity. Moreover, they are not always well characterized and due to the low abundance of the modification, particularly on mRNAs, generated data sets might resemble noise rather than specific modification patterns. Therefore, it is critical that the affinity and specificity is rigorously tested using complementary approaches. Here, we provide an experimental toolbox that allows for testing antibody performance prior to their use. Cold Spring Harbor Laboratory Press 2020-10 /pmc/articles/PMC7491328/ /pubmed/32636310 http://dx.doi.org/10.1261/rna.076026.120 Text en © 2020 Weichmann et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Method Weichmann, Franziska Hett, Robert Schepers, Aloys Ito-Kureha, Taku Flatley, Andrew Slama, Kaouthar Hastert, Florian D. Angstman, Nicholas B. Cardoso, M. Cristina König, Julian Hüttelmaier, Stefan Dieterich, Christoph Canzar, Stefan Helm, Mark Heissmeyer, Vigo Feederle, Regina Meister, Gunter Validation strategies for antibodies targeting modified ribonucleotides |
title | Validation strategies for antibodies targeting modified ribonucleotides |
title_full | Validation strategies for antibodies targeting modified ribonucleotides |
title_fullStr | Validation strategies for antibodies targeting modified ribonucleotides |
title_full_unstemmed | Validation strategies for antibodies targeting modified ribonucleotides |
title_short | Validation strategies for antibodies targeting modified ribonucleotides |
title_sort | validation strategies for antibodies targeting modified ribonucleotides |
topic | Method |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491328/ https://www.ncbi.nlm.nih.gov/pubmed/32636310 http://dx.doi.org/10.1261/rna.076026.120 |
work_keys_str_mv | AT weichmannfranziska validationstrategiesforantibodiestargetingmodifiedribonucleotides AT hettrobert validationstrategiesforantibodiestargetingmodifiedribonucleotides AT schepersaloys validationstrategiesforantibodiestargetingmodifiedribonucleotides AT itokurehataku validationstrategiesforantibodiestargetingmodifiedribonucleotides AT flatleyandrew validationstrategiesforantibodiestargetingmodifiedribonucleotides AT slamakaouthar validationstrategiesforantibodiestargetingmodifiedribonucleotides AT hastertfloriand validationstrategiesforantibodiestargetingmodifiedribonucleotides AT angstmannicholasb validationstrategiesforantibodiestargetingmodifiedribonucleotides AT cardosomcristina validationstrategiesforantibodiestargetingmodifiedribonucleotides AT konigjulian validationstrategiesforantibodiestargetingmodifiedribonucleotides AT huttelmaierstefan validationstrategiesforantibodiestargetingmodifiedribonucleotides AT dieterichchristoph validationstrategiesforantibodiestargetingmodifiedribonucleotides AT canzarstefan validationstrategiesforantibodiestargetingmodifiedribonucleotides AT helmmark validationstrategiesforantibodiestargetingmodifiedribonucleotides AT heissmeyervigo validationstrategiesforantibodiestargetingmodifiedribonucleotides AT feederleregina validationstrategiesforantibodiestargetingmodifiedribonucleotides AT meistergunter validationstrategiesforantibodiestargetingmodifiedribonucleotides |